Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (71-80 of 159) with videos related to

Pageof 16
Sort By:
Arthritis Care & Research|August 5, 2015
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III TrialsBernard Combe, Daniel E Furst, Edward C Keystone, et al.
Rheumatology (Oxford, England)|November 19, 2013
Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohortTommy Choy, Vivian P Bykerk, Gilles Boire, et al.
The Journal of Rheumatology|September 4, 2012
Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH studyLonnie Pyne, Vivian P Bykerk, Gilles Boire, et al.
Plos One|August 21, 2009
Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapyCarole L Galligan, Janet C Siebert, Katherine A Siminovitch, et al.
The Journal of Rheumatology|January 17, 2018
The Dorsal 4-finger Technique: A Novel Method to Examine Metacarpophalangeal Joints in Patients with Rheumatoid ArthritisMohammed A Omair, Pooneh Akhavan, Ali Naraghi, et al.
Rheumatology (Oxford, England)|February 7, 2014
Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohortMichael B Arnold, Vivian P Bykerk, Gilles Boire, et al.
The Journal of Rheumatology|February 5, 2013
Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomesLillian Barra, Vivian Bykerk, Janet E Pope, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trialPhilip G Conaghan, Paul Emery, Mikkel Østergaard, et al.
Journal of Clinical Epidemiology|May 1, 2010
Response times follow lognormal or gamma distribution in arthritis patientsLusine Abrahamyan, Joseph Beyene, JingYuan Feng, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Pageof 16

Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
Arthritis Care & Research|August 5, 2015
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III TrialsBernard Combe, Daniel E Furst, Edward C Keystone, et al.
Rheumatology (Oxford, England)|November 19, 2013
Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohortTommy Choy, Vivian P Bykerk, Gilles Boire, et al.
The Journal of Rheumatology|September 4, 2012
Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH studyLonnie Pyne, Vivian P Bykerk, Gilles Boire, et al.
Plos One|August 21, 2009
Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapyCarole L Galligan, Janet C Siebert, Katherine A Siminovitch, et al.
The Journal of Rheumatology|January 17, 2018
The Dorsal 4-finger Technique: A Novel Method to Examine Metacarpophalangeal Joints in Patients with Rheumatoid ArthritisMohammed A Omair, Pooneh Akhavan, Ali Naraghi, et al.
Rheumatology (Oxford, England)|February 7, 2014
Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohortMichael B Arnold, Vivian P Bykerk, Gilles Boire, et al.
The Journal of Rheumatology|February 5, 2013
Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomesLillian Barra, Vivian Bykerk, Janet E Pope, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trialPhilip G Conaghan, Paul Emery, Mikkel Østergaard, et al.
Journal of Clinical Epidemiology|May 1, 2010
Response times follow lognormal or gamma distribution in arthritis patientsLusine Abrahamyan, Joseph Beyene, JingYuan Feng, et al.
Arthritis Research & Therapy|November 14, 2009
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trialVibeke Strand, Philip Mease, Gerd R Burmester, et al.
Pageof 16